Australia-based Neuren Pharmaceuticals has confirmed the primary goals for its double-blind, single Phase III pivotal trial of its drug NNZ-2591 in treating Phelan-McDermid syndrome (PMS) for 13 weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results